PVX-001 Phase I Trial Doses 14 Participants Under ACTRN12626000891325 with Zero SAEs Reported
PVX-001 entered first-in-human testing on 31 August 2026. 14 participants have been dosed with no SAEs. Platform data will gate open-source release and four additional vaccine programs.
PopVax advanced its mRNA-encoded VLP candidate built on an in-house computational protein design pipeline, PVXL-150 ionizable lipid, and Hyderabad RNA Foundry process. The 36-participant trial measures safety, tolerability, and breadth of neutralizing responses against multiple SARS-CoV-2 variants. All components were developed internally over 4.5 years without reliance on licensed platform technology.
Registry data and the company chronicle confirm first-in-human dosing occurred after Gates Foundation and Balvi seed funding. Earlier mRNA vaccines showed rapid efficacy loss against variants; PVX-001 targets conserved epitopes via VLP display. Open-source release is scheduled only after Phase I completion, limiting immediate external replication.
Operational impact centers on platform validation. Positive immunogenicity data would de-risk parallel programs including single-dose rabies, multivalent HCV, adult TB, and Strep A vaccines slated for IND filings within 24 months. The 1 million lives per year target requires at least three additional candidates to reach licensure by 2031.
PopVax: Phase I immunogenicity readout by March 2027 shows >4-fold neutralization breadth against three variants in at least 70% of participants.
Sources (2)
- [1]Primary Source(https://chronicles.popvax.com/p/popvax-goes-clinical)
- [2]Supporting Source(https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12626000891325)